257 related articles for article (PubMed ID: 26582375)
1. Complement in hemolytic anemia.
Brodsky RA
Blood; 2015 Nov; 126(22):2459-65. PubMed ID: 26582375
[TBL] [Abstract][Full Text] [Related]
2. Complement in hemolytic anemia.
Brodsky RA
Hematology Am Soc Hematol Educ Program; 2015; 2015():385-91. PubMed ID: 26637747
[TBL] [Abstract][Full Text] [Related]
3. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
Merrill SA; Brodsky RA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):371-376. PubMed ID: 30504334
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
Risitano AM; Marotta S
Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
[TBL] [Abstract][Full Text] [Related]
5. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
6. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
7. Complement and the prothrombotic state.
Schmidt CQ; Schrezenmeier H; Kavanagh D
Blood; 2022 Mar; 139(13):1954-1972. PubMed ID: 34415298
[TBL] [Abstract][Full Text] [Related]
8. Molecular pharmacology in complement-mediated hemolytic disorders.
Bortolotti M; Barcellini W; Fattizzo B
Eur J Haematol; 2023 Sep; 111(3):326-336. PubMed ID: 37308291
[TBL] [Abstract][Full Text] [Related]
9. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria.
Hall SE; Rosse WF
Blood; 1996 Jun; 87(12):5332-40. PubMed ID: 8652849
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection.
Dammermann W; Schipper P; Ullrich S; Fraedrich K; Schulze Zur Wiesch J; Fründt T; Tiegs G; Lohse A; Lüth S
PLoS One; 2013; 8(9):e74880. PubMed ID: 24086391
[TBL] [Abstract][Full Text] [Related]
12. Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria.
DeZern AE; Uknis M; Yuan X; Mukhina GL; Varela J; Saye J; Pu J; Brodsky RA
Exp Hematol; 2014 Oct; 42(10):857-61.e1. PubMed ID: 25034232
[TBL] [Abstract][Full Text] [Related]
13. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.
Laurence J; Haller H; Mannucci PM; Nangaku M; Praga M; Rodriguez de Cordoba S
Clin Adv Hematol Oncol; 2016 Nov; 14 Suppl 11(11):2-15. PubMed ID: 27930620
[TBL] [Abstract][Full Text] [Related]
14. Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes.
Meletis J; Terpos E; Samarkos M; Meletis C; Apostolidou E; Komninaka V; Korovesis K; Mavrogianni D; Boutsis D; Variami E; Viniou N; Konstantopoulos K; Loukopoulos D
Hematol J; 2001; 2(1):33-7. PubMed ID: 11920231
[TBL] [Abstract][Full Text] [Related]
15. Modified Ham test for atypical hemolytic uremic syndrome.
Gavriilaki E; Yuan X; Ye Z; Ambinder AJ; Shanbhag SP; Streiff MB; Kickler TS; Moliterno AR; Sperati CJ; Brodsky RA
Blood; 2015 Jun; 125(23):3637-46. PubMed ID: 25862562
[TBL] [Abstract][Full Text] [Related]
16. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.
Phillips EH; Westwood JP; Brocklebank V; Wong EK; Tellez JO; Marchbank KJ; McGuckin S; Gale DP; Connolly J; Goodship TH; Kavanagh D; Scully MA
J Thromb Haemost; 2016 Jan; 14(1):175-85. PubMed ID: 26559391
[TBL] [Abstract][Full Text] [Related]
17. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
Sridharan M; Go RS; Willrich MAV
J Immunol Methods; 2018 Oct; 461():15-22. PubMed ID: 30031798
[TBL] [Abstract][Full Text] [Related]
18. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
Kistler AD
Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
[TBL] [Abstract][Full Text] [Related]
19. Complementopathies.
Baines AC; Brodsky RA
Blood Rev; 2017 Jul; 31(4):213-223. PubMed ID: 28215731
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the survival of paroxysmal nocturnal hemoglobinuria red cells through the immunophenotyping of reticulocytes.
Navenot JM; Muller JY; Blanchard D
Transfusion; 1998 Apr; 38(4):337-42. PubMed ID: 9595015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
